Sanofi says Beyfortus RSV study in babies met endpoints

Sanofi (SNY) says the largest U.S. real-world study of Beyfortus met both of its co-primary endpoints, demonstrating the drug provides protection for babies against RSV disease. The first co-primary endpoint showed babies administered Beyfortus were 87% less likely to develop RSV disease compared to babies who did not receive Beyfortus. The second co-primary endpoint showed that if a baby who received Beyfortus later tested positive for RSV lung infection there were fewer overall medical visits during the illness, Sanofi announced. The study included more than 30,000 healthy, full-term babies.